H.C. Wainwright raised the firm’s price target on Ocular Therapeutix (OCUL) to $15 from $14 and keeps a Buy rating on the shares following the Q3 report. The firm says SOL-1 is slated to complete enrollment by the end of 2024 with topline data expected in Q4 of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL: